Clinical Trial Search

Primary: Number of Subjects With an Immune Response to Different Meningococcal Serogroups — 30; 32; 26; 27 Participants

Primary: The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study. — 1; 1; 6 Participants

Primary: Event-free Survival — 0.614; 0.685; 0.372 Probability of EFS at 5 years

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After End of Study Drug Treatment (SVR12) — 86.4; 100 Percentage of Participants

Primary: Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB) — 18.8; 22.2 ng/mL

Primary: Kidney Disease Quality of Life (KDQOL-36) Mean Scale Scores at Baseline, 6, 12 and 18 Months: Unadjusted — 35.5; 38.4; 36.3; 36.8 units on a scale

Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants

Primary: Accuracy, Sensitivity, and Specificity for Differentiating Neoplastic and Non-neoplastic Lesions — 94.3; 98.0; 92.0 percentage of lesions

Primary: Progression-Free Survival — 3.0 months

Primary: Progression-free Survival — 3.5; 5.4 Months

Primary: Percentage of Participants With Event (Death) — 77.0; 75.5 percentage of participants

Primary: Remitters as Assessed by Post-treatment Beck Depression Inventory Less Than or Equal to 10 — 13 Participants

Primary: The Efficacy (Defined as Prevention of Infection) of the HP Vaccine Compared to Placebo. — 0; 0; 21; 8 Percentage of subjects

Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes — 0.37; 0.31; 4.78; 5.98 µg/mL

Primary: Evaluate the Total Volume of CM Used Comparing the DyeVert Group to the Control Group. — 38.0; 62.5 ml